Skip Nav Destination
Issues
1 June 2018
-
Cover Image
Cover Image
Cervical cancer is a leading cause of death in underserved areas of Brazil, which are often located thousands of kilometers from the nearest facility where diagnostic follow-up and treatment are administered. In the northern part of São Paulo state, Barretos Cancer Hospital has been a pioneer in new mobile strategies for cervical cancer prevention–instead of requiring each patient to travel long distances to a central facility, a mobile vehicular clinic makes routine visits to see patients in their city. While this approach overcomes geographical limitations, new technological innovations are required to administer cervical cancer care in remote locations without compromise in the quality of care. Hunt et al (page 359) report on a cluster randomized trial involving a mobile diagnostic van equipped with a tablet-interfaced in vivo microscope. This microscope is a low-cost fiber-optic imaging device that can assess subcellular morphologic features in real time and plays an important role in this mobile strategy. The micrograph featured on the cover of this issue was acquired from a suspected cancer precursor lesion using the in vivo microscope and correctly identified by the automated analysis algorithm as requiring treatment. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Editorial
Research Articles
Diagnosing Cervical Neoplasia in Rural Brazil Using a Mobile Van Equipped with In Vivo Microscopy: A Cluster-Randomized Community Trial
Brady Hunt; José Humberto Tavares Guerreiro Fregnani; Richard A. Schwarz; Naitielle Pantano; Suelen Tesoni; Júlio César Possati-Resende; Marcio Antoniazzi; Bruno de Oliveira Fonseca; Graziela de Macêdo Matsushita; Cristovam Scapulatempo-Neto; Ligia Kerr; Philip E. Castle; Kathleen Schmeler; Rebecca Richards-Kortum
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.